Limits...
Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment.

Strand V, Sharp V, Koenig AS, Park G, Shi Y, Wang B, Zack DJ, Fiorentino D - Ann. Rheum. Dis. (2012)

Bottom Line: Baseline comparisons with age and gender-matched norms and treatment-associated changes in domain scores were quantified using spydergrams and the health utility SF-6D measure.Treatment with etanercept resulted in improvements in PCS and MCS scores as well as individual SF-36 domains across all indications.Treatment with etanercept was associated with improvements in PCS and MCS scores as well as individual domain scores in patients with RA, PsA and psoriasis.

View Article: PubMed Central - PubMed

Affiliation: Division of Immunology/Rheumatology, Stanford University, 306 Ramona Road, Portola Valley, CA 94028, USA. vstrand@stanford.edu

ABSTRACT

Objectives: To compare health-related quality of life (HRQoL) before and after treatment with etanercept in patients with moderate to severe rheumatoid arthritis (RA), psoriatic arthritis (PsA) and psoriasis using spydergram representations.

Methods: Data from randomised, controlled trials of etanercept in patients with RA, PsA and psoriasis were analysed. HRQoL was assessed by the medical outcomes survey short form 36 (SF-36) physical (PCS) and mental (MCS) component summary and domain scores. Baseline comparisons with age and gender-matched norms and treatment-associated changes in domain scores were quantified using spydergrams and the health utility SF-6D measure.

Results: Mean baseline PCS scores were lower than age and gender-matched norms in patients with RA and PsA, but near normative values in patients with psoriasis; MCS scores at baseline were near normal in PsA and psoriasis but low in RA. Treatment with etanercept resulted in improvements in PCS and MCS scores as well as individual SF-36 domains across all indications. Mean baseline SF-6D scores were higher in psoriasis than in RA or PsA; clinically meaningful improvements in SF-6D were observed in all three patient populations following treatment with etanercept.

Conclusions: Patients with RA, PsA and psoriasis demonstrated unique HRQoL profiles at baseline. Treatment with etanercept was associated with improvements in PCS and MCS scores as well as individual domain scores in patients with RA, PsA and psoriasis.

Show MeSH

Related in: MedlinePlus

Short form 36 (SF-36) spydergrams for patients with psoriasis. Mean SF-36 scores at baseline and week 12 of the randomised controlled trial (RCT) portion of the clinical trial and age and gender-matched norms are shown for patients receiving (A) placebo, (B) etanercept 25 mg twice a week (BIW), or (C) etanercept 50 mg twice a week. Mean SF-36 scores at baseline and weeks 12 and 24 of the open-label (OL) portion of the trial (when all patients received etanercept 25 mg twice a week) are shown for patients who had received (D) placebo, (E) etanercept 25 mg twice a week, or (F) etanercept 50 mg twice a week during the RCT portion of the trial. Mean SF-36 scores for age and gender-matched norms are also shown.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC3375587&req=5

Figure 3: Short form 36 (SF-36) spydergrams for patients with psoriasis. Mean SF-36 scores at baseline and week 12 of the randomised controlled trial (RCT) portion of the clinical trial and age and gender-matched norms are shown for patients receiving (A) placebo, (B) etanercept 25 mg twice a week (BIW), or (C) etanercept 50 mg twice a week. Mean SF-36 scores at baseline and weeks 12 and 24 of the open-label (OL) portion of the trial (when all patients received etanercept 25 mg twice a week) are shown for patients who had received (D) placebo, (E) etanercept 25 mg twice a week, or (F) etanercept 50 mg twice a week during the RCT portion of the trial. Mean SF-36 scores for age and gender-matched norms are also shown.

Mentions: Overall, patients with psoriasis reported lower reductions in physical and mental domains of SF-36 than patients with RA or PsA, and baseline SF-36 domain scores approximated normal values in most domains (figure 3A–C). The lowest scores were in the BP, GH, VT and MH domains. Despite high values at baseline, after 12 weeks of treatment, improvements were reported in all domains and clinically meaningful improvements were reported in all domains except GH in patients receiving etanercept at either dose. In both active treatment groups, the largest mean changes were reported in BP (14.6 points and 16.5 points for etanercept 25 mg twice a week and 50 mg twice a week, respectively), SF (8.9 points and 13.8 points), RP (9.8 points and 13.1 points) and RE (10.5 points and 10.4 points) domains. No statistically significant or clinically meaningful changes were reported in patients receiving placebo. During the open-label phase of the trial, patients who had initially received etanercept at either dose maintained their improvements and patients who initially received placebo achieved clinically meaningful improvements in all domains but PF and GH (figure 3D–F).


Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment.

Strand V, Sharp V, Koenig AS, Park G, Shi Y, Wang B, Zack DJ, Fiorentino D - Ann. Rheum. Dis. (2012)

Short form 36 (SF-36) spydergrams for patients with psoriasis. Mean SF-36 scores at baseline and week 12 of the randomised controlled trial (RCT) portion of the clinical trial and age and gender-matched norms are shown for patients receiving (A) placebo, (B) etanercept 25 mg twice a week (BIW), or (C) etanercept 50 mg twice a week. Mean SF-36 scores at baseline and weeks 12 and 24 of the open-label (OL) portion of the trial (when all patients received etanercept 25 mg twice a week) are shown for patients who had received (D) placebo, (E) etanercept 25 mg twice a week, or (F) etanercept 50 mg twice a week during the RCT portion of the trial. Mean SF-36 scores for age and gender-matched norms are also shown.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC3375587&req=5

Figure 3: Short form 36 (SF-36) spydergrams for patients with psoriasis. Mean SF-36 scores at baseline and week 12 of the randomised controlled trial (RCT) portion of the clinical trial and age and gender-matched norms are shown for patients receiving (A) placebo, (B) etanercept 25 mg twice a week (BIW), or (C) etanercept 50 mg twice a week. Mean SF-36 scores at baseline and weeks 12 and 24 of the open-label (OL) portion of the trial (when all patients received etanercept 25 mg twice a week) are shown for patients who had received (D) placebo, (E) etanercept 25 mg twice a week, or (F) etanercept 50 mg twice a week during the RCT portion of the trial. Mean SF-36 scores for age and gender-matched norms are also shown.
Mentions: Overall, patients with psoriasis reported lower reductions in physical and mental domains of SF-36 than patients with RA or PsA, and baseline SF-36 domain scores approximated normal values in most domains (figure 3A–C). The lowest scores were in the BP, GH, VT and MH domains. Despite high values at baseline, after 12 weeks of treatment, improvements were reported in all domains and clinically meaningful improvements were reported in all domains except GH in patients receiving etanercept at either dose. In both active treatment groups, the largest mean changes were reported in BP (14.6 points and 16.5 points for etanercept 25 mg twice a week and 50 mg twice a week, respectively), SF (8.9 points and 13.8 points), RP (9.8 points and 13.1 points) and RE (10.5 points and 10.4 points) domains. No statistically significant or clinically meaningful changes were reported in patients receiving placebo. During the open-label phase of the trial, patients who had initially received etanercept at either dose maintained their improvements and patients who initially received placebo achieved clinically meaningful improvements in all domains but PF and GH (figure 3D–F).

Bottom Line: Baseline comparisons with age and gender-matched norms and treatment-associated changes in domain scores were quantified using spydergrams and the health utility SF-6D measure.Treatment with etanercept resulted in improvements in PCS and MCS scores as well as individual SF-36 domains across all indications.Treatment with etanercept was associated with improvements in PCS and MCS scores as well as individual domain scores in patients with RA, PsA and psoriasis.

View Article: PubMed Central - PubMed

Affiliation: Division of Immunology/Rheumatology, Stanford University, 306 Ramona Road, Portola Valley, CA 94028, USA. vstrand@stanford.edu

ABSTRACT

Objectives: To compare health-related quality of life (HRQoL) before and after treatment with etanercept in patients with moderate to severe rheumatoid arthritis (RA), psoriatic arthritis (PsA) and psoriasis using spydergram representations.

Methods: Data from randomised, controlled trials of etanercept in patients with RA, PsA and psoriasis were analysed. HRQoL was assessed by the medical outcomes survey short form 36 (SF-36) physical (PCS) and mental (MCS) component summary and domain scores. Baseline comparisons with age and gender-matched norms and treatment-associated changes in domain scores were quantified using spydergrams and the health utility SF-6D measure.

Results: Mean baseline PCS scores were lower than age and gender-matched norms in patients with RA and PsA, but near normative values in patients with psoriasis; MCS scores at baseline were near normal in PsA and psoriasis but low in RA. Treatment with etanercept resulted in improvements in PCS and MCS scores as well as individual SF-36 domains across all indications. Mean baseline SF-6D scores were higher in psoriasis than in RA or PsA; clinically meaningful improvements in SF-6D were observed in all three patient populations following treatment with etanercept.

Conclusions: Patients with RA, PsA and psoriasis demonstrated unique HRQoL profiles at baseline. Treatment with etanercept was associated with improvements in PCS and MCS scores as well as individual domain scores in patients with RA, PsA and psoriasis.

Show MeSH
Related in: MedlinePlus